Vascular cognitive impairment and dementia (VCID) is currently the second most common type of dementia just after Alzheimer's disease (AD). 1 In 2015, approximately 47.5 million people were affected by dementia, which is expected to increase to 75.6 million by 2030. The annual global social cost for VCID and vascular dementia (VaD) is $604 billion, accounting for 1.0% of the global gross domestic product. 2 Vascular cognitive impairment and dementia occurs when cerebral blood flow is compromised. It is a comprehensive brain disorder that comprises mild cognitive impairment (MCI), VaD, and mixed dementia, such as mixed vascular and AD-type cognitive impairment. 3 VCID presents a significant decline in cognitive function due to cerebral vascular damage, including clinical stroke, asymptomatic infarcts and microinfarcts, leukoaraiosis, cerebral amyloid angiopathy (CAA), 4 transient ischemic attack (TIA), and micro hemorrhage. 5 Diagnosis is further defined according to whether there is a causal relationship between cognitive impairment syndrome and vascular disease. 6,7 Up to now, treatment for VCID is still limited to relief and therapy of symptoms. 8 For example, Donepezil was found to enhance the cognitive ability of VaD patients. 3 Administration of Galantamine is beneficial for patients with mixed AD and VaD. 9 Non-coding RNAs, especially miRs, are one of the many biological factors that cause functional changes during VCID. Because of